Summary of Key Points
Over the next five years, China's medical insurance system will promote the pharmaceutical industry into an "value-oriented" innovation cycle through comprehensive and systematic policy support. The National Medical Insurance Administration has outlined a support framework in its 14th Five-Year Plan that covers six areas: data openness, unified drug catalogs, pricing autonomy, payment reform, commercial insurance supplementation, and international market expansion platforms. This framework transforms the previously fragmented and ad-hoc support measures into a well-structured strategic approach, enabling medical insurance—the largest purchaser in the pharmaceutical sector—to reshape the entire industry with a value-based perspective.
Detailed Interpretation
1. Openness of Medical Insurance Data: Helping Pharmaceutical Companies with Targeted Research and Development
Medical insurance holds billions of records on drug usage by real patients. In the past, companies might develop new drugs based on popular targets (such as PD-1 for cancer treatment), leading to significant homogenization and wasted resources without effective results. By making this data available to pharmaceutical companies and research institutions, medical insurance can help them:
- Identify unmet clinical needs.
- Discover new drug targets by analyzing actual usage patterns.
- Optimize their R&D pipelines, reducing the need for blind following of popular trends and minimizing competition.
Although the exact implementation of this data-sharing model is still being developed, the direction is clear: using real data to guide R&D efforts and make innovation more efficient.
2. Autonomous Pricing for High-Value Innovations
Previously, innovative drugs had to be significantly discounted to be included in medical insurance, often resulting in unprofitable investments for companies. The new plan allows high-value innovations to set their own prices:
- Companies can assess the level of innovation and receive different policies based on whether their products are considered "high-level innovations," "improved versions," or generic drugs.
- Prices can be set to reflect the costs and risks associated with development, ensuring stability in the initial market phase.
- New medical technologies, such as surgical robots and brain-computer interfaces, can quickly be included in the insurance coverage system through pre-approved processes, making them more accessible to both hospitals and patients.
This change provides pharmaceutical companies with confidence that they can make a profit if their products are truly effective, thus encouraging more investment in innovation.
3. Unified National Medical Insurance Catalog
The previous fragmentation of medical insurance catalogs across provinces (especially for medical supplies and services) made it costly for companies to market their products nationwide. The new plan aims to standardize these catalogs at the national level:
- Medical service items and supplies will be regulated uniformly.
- Innovative drugs that meet the criteria can be included in the national catalog, making them readily available across the country without the need for separate negotiations with each province.
This change eliminates regional barriers and facilitates faster and more cost-effective market entry for innovative products.
4. Commercial Insurance Supplementation and International Market Expansion
Basic medical insurance covers essential needs, but some expensive innovations may not be covered. The plan addresses this issue through two approaches:
- Commercial Insurance Supplementation: A separate catalog for innovative drugs is established, which is not affected by price controls or centralized procurement, allowing companies to set their own prices.
- Data sharing between medical insurance and commercial insurers ensures faster and more convenient reimbursement for patients.
This creates an additional payment channel for innovative drugs, enabling them to reach a wider market.
5. Payment Reform
The method of medical insurance payments is also being adjusted to encourage the use of innovative products:
- The integration of Diagnosis-Related Groups (DRG) and Disease Intervention Points (DIP) systems will be implemented, with periodic updates every two years.
- This flexibility ensures that hospitals and doctors are incentivized to use innovative drugs and technologies, facilitating their quicker adoption in clinical practice.
In summary, the core of the 14th Five-Year Plan is to shift from a price-based to a value-based approach. Instead of focusing solely on cost, medical insurance will prioritize the clinical effectiveness and level of innovation of drugs. With comprehensive policy support, pharmaceutical companies will be more motivated to innovate, and innovative medicines will reach patients more quickly, while also opening up international markets for Chinese pharmaceutical products.
Over the next five years, the innovation momentum in the pharmaceutical industry is expected to increase, benefiting both patients and the industry as a whole.